logo
Singapore's Temasek mulls major overhaul to boost returns

Singapore's Temasek mulls major overhaul to boost returns

Singapore 's Temasek Holdings is mulling one of its biggest overhauls in years, potentially reorganising the firm into three investment vehicles in a bid to boost returns and efficiencies, according to people familiar with the matter.
Advertisement
Under the proposal still being discussed at senior levels, Singapore's state-owned investor could divide its business into three arms. One would focus on
Temasek 's biggest domestic holdings, such as
Singapore Airlines , and another would oversee largely foreign investments. A third unit would include all of Temasek's fund investments, said the people who asked not to be identified, discussing a private matter.
The move, which remains fluid and subject to change, would fundamentally restructure the 51-year-old investment giant amid rising pressure to deliver higher returns and streamline its operations.
While Temasek's net portfolio value hit a record high of S$434 billion (US$338 billion) as of March 31, its 10-year total shareholder return of 5 per cent – a compounded and annualised measure that includes dividends – just matched that of its larger but more conservative Singaporean peer GIC Pte. It underperformed the MSCI World Index, which returned an annualised 10 per cent in the decade through March 2025.
Temasek is currently run in a conventional manner, with different executives responsible for investing across various assets and geographies, such as real estate or
China . If the reorganisation proceeds, it would enable key executives to better focus their attention on improving the firm's performance and efficiency, the people said.
Advertisement
Temasek didn't immediately respond to a request for comment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bank of East Asia profits rise as wealth business offsets bad property loans in Hong Kong
Bank of East Asia profits rise as wealth business offsets bad property loans in Hong Kong

South China Morning Post

time29 minutes ago

  • South China Morning Post

Bank of East Asia profits rise as wealth business offsets bad property loans in Hong Kong

Bank of East Asia (BEA), Hong Kong's largest family-owned lender, beat expectations with 14 per cent growth in its first-half net profit, as a robust wealth-management business offset an increase in bad debt from commercial real estate. Advertisement The bank recorded HK$2.41 billion (US$309 million) in net profit for the six months to June, or 86 HK cents per share, compared with HK$2.11 billion a year earlier, according to a stock exchange filing on Thursday. Analysts had expected 11 per cent profit growth. The bank will pay an interim dividend of 39 HK cents per share, 25.8 per cent higher than a year earlier. A 16 per cent increase in fee income from the sale of insurance, wealth-management products and structured products drove the growth, bringing in HK$1.65 billion, the bank reported. This was offset by an increase in bad debt provisions for commercial property loans, as Hong Kong's non-performing-loan ratio in the sector rose to 7.5 per cent in June from 6 per cent in December, the bank said. In addition, 10 per cent of the sector's outstanding loans were classified as risky, it added. Advertisement 'We are very cautious about the commercial real estate loans made in Hong Kong, and cannot rule out a continuing rise in the non-performing loan ratio,' BEA's co-CEO Adrian Li Man-kiu said in a results briefing. Amid weak demand for office and retail space, HSBC, Hang Seng Bank and Standard Chartered also revealed higher provisions for commercial-property loans in their first-half results.

China vows stronger biotech support as deals with global pharmaceutical giants surge
China vows stronger biotech support as deals with global pharmaceutical giants surge

South China Morning Post

timean hour ago

  • South China Morning Post

China vows stronger biotech support as deals with global pharmaceutical giants surge

Chinese Premier Li Qiang has called for stronger policy support for the biotech industry, as part of efforts to bolster innovation in a sector that has witnessed a boom in recent years. 'The biopharmaceutical industry is both a strategic emerging sector and vital to public health,' he said during an inspection in Beijing on Wednesday, as reported by the state-run Xinhua News Agency. 'Efforts should be made to strengthen original innovation, address core technological challenges and mobilise resources from the government and market to achieve breakthroughs quickly.' Li also urged research institutes to focus on global frontiers and critical areas, while training top talent to establish a solid foundation for the sector's development. His remarks came as Chinese biotech developers continue to sign increasing numbers of out-licensing agreements with multinational pharmaceutical companies. Out-licensing involves biotech firms selling drug candidates, which have often completed Phase I and II trials in China, to global partners. Chinese drug developers have widely adopted the model to ease financial pressures in an industry where embracing new therapeutic approaches has proven cash-intensive and carries a high risk of failure. With China's healthcare system largely government-funded, steep price cuts under its national insurance scheme also limit domestic profitability.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store